Project Description

Overview

In July 2018, the TB CARE II team held the second USAID Drug-Resistant Tuberculosis Scientific Forum. Attended by a diverse group of stakeholders, reviewed the routine use of injectable agents for rifampin-resistant TB (RR-TB), and discussed emerging data on potential alternatives. Organized into two parts, participants focused on existing evidence including personal experiences, efficacy, safety, and the human rights implications of the routine use of the injectables for the treatment of all persons with RR-TB and presentations of new and emerging evidence from recent cohorts including EndTB, South Africa, and Swaziland.